Everything below concerns GHRH analog. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue peptide | GHRH analog backbone |
| Approximate molecular mass | 5136 Da | Varies with counterion and hydration state |
| N-terminal group | trans-3-hexenoyl | Increases resistance to dipeptidyl peptidase IV |
| Primary receptor | GHRH receptor (GHRHR) | Class B G protein-coupled receptor on somatotrophs |
| Principal mediator | IGF-1 | Rises indirectly after growth hormone release |
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
To describe the types of protein–protein interactions (PPIs), proteins can interact in a "transient" way (to produce some specific effect in a short time, like signal transduction) or to interact with other proteins in a "stable" way to form complexes that become molecular machines within the living systems. A protein complex assembly can result in the formation of homo-oligomeric or hetero-oligomeric complexes. In addition to the conventional complexes, as enzyme-inhibitor and antibody-antigen, interactions can also be established between domain-domain and domain-peptide. Another important distinction to identify protein–protein interactions is the way they have been determined, since there are techniques that measure direct physical interactions between protein pairs, named "binary" methods, while there are other techniques that measure physical interactions among groups of proteins, without pairwise determination of protein partners, named "co-complex" methods.
=== BIT Index === The branched:isoprenoid tetraether (BIT) index relates the relative abundances of brGDGTs in a natural sample to the relative abundance of soil organic matter in that sample. It is calculated by ratioing a sum of bacterially-produced brGDGT abundances over a sum of archaeal isoGDGT abundances and is based on the fundamental idea that brGDGTs are produced most commonly in terrestrial environments (most ubiquitous in soils and peats) while archaeal isoGDGTs (particularly crenarchaeol) are produced in marine environments. While caveats and analytical uncertainties remain an issue, the BIT index is a potentially useful proxy for assessing the amount of fluvially transported soil organic matter compared to marine organic matter.
People convicted of murder, drug trafficking, corruption or human rights violations will not qualify under the amnesty law. The measure was long requested by the US-backed Venezuelan opposition. Opposition leader María Corina Machado said that the bill was not taken "voluntarily, but rather in response to pressure from the US government". Rodríguez also announced the shutdown of El Helicoide prison, which she said would be transformed into a cultural and sport center. Independent organizations have documented many cases of torture and human rights violation in El Helicoide. Family of some of the prisoners gathered outside El Helicoide chanting "Freedom!". Venezuelan opposition politician and ally of Machado, Juan Pablo Guanipa, was released from prison on 8 February but taken by unknown armed groups hours later; by 10 February, his family confirmed he was under house arrest in Maracaibo, calling the measure unjust detention. On 19 February, the amnesty law was approved by the National Assembly of Venezuela. Jorge Rodríguez said that over 1557 request liberty a day after. Juan Pablo Guanipa was also released from house arrest. During the 2026 State of the Union Address, Trump invited Venezuelan politician Enrique Márquez, who was imprisoned in 2025 and was released in early January. Trump said "Since the raid we have worked with the new leadership and they have ordered the closure of that vile prison and released hundreds of political prisoners already, with more to come."
Because a dalton, a unit commonly used to measure atomic mass, is exactly 1/12 of the mass of a carbon-12 atom, this definition of the mole entailed that the mass of one mole of a compound or element in grams was numerically equal to the average mass of one molecule or atom of the substance in daltons, and that the number of daltons in a gram was equal to the number of elementary entities in a mole. Because the mass of a nucleon (i.e. a proton or neutron) is approximately 1 dalton and the nucleons in an atom's nucleus make up the overwhelming majority of its mass, this definition also entailed that the mass of one mole of a substance was roughly equivalent to the number of nucleons in one atom or molecule of that substance. Since the definition of the gram was not mathematically tied to that of the dalton, the number of molecules per mole NA (the Avogadro constant) had to be determined experimentally. The experimental value adopted by CODATA in 2010 is NA = 6.02214129(27)×1023 mol−1. In 2011 the measurement was refined to 6.02214078(18)×1023 mol−1. The mole was made the seventh SI base unit in 1971 by the 14th CGPM.
GCH Retail (Malaysia) Sdn Bhd, doing business as Giant Mall, is a hypermarket brand and retailer chain now mainly in Malaysia, Singapore and formerly Brunei, Cambodia, Indonesia and Vietnam. In 2016, Giant was the largest supermarket chain in Malaysia. Its parent company also operates Mercató, Cold Storage and TMC in Malaysia.
Sources: en.wikipedia.org
On October 21, 2025, Gallrein announced his candidacy for the United States House of Representatives for Kentucky's 4th congressional district, challenging seven-term incumbent Thomas Massie in the Republican primary. Massie had held the seat since 2012, and was considered to be popular within the district; in 2024 he had won the Republican primary with 76% of the vote, and the general election with 99.6% of the vote. President Donald Trump endorsed Gallrein on October 17, 2025. The primary was the most expensive congressional primary in U.S. history, costing over $25 million. Gallrein won the Republican nomination on May 19, 2026, 54.9%–45.1%, winning 19 of the 21 counties that voted. After the race against Massie was called in Gallrein's favor, Gallrein said: "It was a David versus Goliath. I was the underdog." Gallrein will face Democrat Melissa Strange in the general election on November 3, 2026.
"The fibrous variant of Hashimoto's thyroiditis" (1974, with Austin L. Vickery Jr.) "Thymoma in a 12-year-old boy" (1976, with Jane Chatten) "Urinary Ultrastructural Findings in Fabry Disease" (1977, with Patricia J. Lyons) "Examination of Sputum in Legionnaire's Disease" (1978) "Legionnaires' disease: structural characteristics of the organism" (1978, with Philip Nash) "Leydig cell tumors of the testis" (1979, with I. Damjanov and M. A. Jewett) "Ultrastructural Features of Respiratory Cilia in Cystic Fibrosis" (1980, with Douglas S. Holsclaw Jr.) "Postinflammatory pseudotumors of the lung: fibrous histiocytoma and related lesions" (1980, with E. E. Schwartz and G. A. Mandell) "Tolmetin: Association With Reversible Renal Failure and Acute Interstitial Nephritis" (1981, with Ralph Capaldo, Erich A. Everts, and John G. DiGregorio) "Pleomorphism of Legionella pneumophila" (1984, with Shahab Hashemi, Kristy R. Brown, William A. Habib, and Jay M. Hammel) "Cilia in the Human Kidney" (1984, with Joseph J. Morgan) Legionellosis (1985) "Microscopic Nephrocalcinosis in Cystic Fibrosis" (1988, with Leslie J. Krueger and Bonita L. Falkner) "A Self-Limited Febrile Illness Produced in Guinea Pigs Associated With Oral Administration of Legionella pneumophila" (1988, with Jay M. Hammel, Joseph P. Matus, Ronald Poropatich, and Julian Katz) "Diagnostic value of electron microscopy on paraffin-embedded cytologic material" (1993, with Nancy A. Young and Sonya Naryshkin)
== Applications == Aerosol science and measurements field, especially aerosol mass spectrometry has grown a lot over the last couple decades. Its growth is partly due to the instruments versatility, it has the ability to analyze a particles size and chemical composition, and perform bulk and single-particle measurements. The versatility of aerosol mass spectrometers allow for them to be used for many different applications in both the lab and field. Over the years aerosols mass spectrometers have been used for anything from determining emissions sources, human exposure to pollutants, radiative transfer and cloud microphysics. Most of these studies have utilized the mobility of the AMS and has been fielded in urban, remote, rural, marine, and forested environments around the world. AMS have also been deployed in mobile platforms such as ships, mobile laboratories, and aircraft. One recent emission study in 2014 was performed by two NASA research aircraft, a DC-8 and a P-3B, that were outfitted with aerosol instrumentation (AMS). The aircraft were sent to perform analysis of atmospheric samples over the oil sands mining and upgrading facilities near Ft. McMurray, Alberta, Canada. The purpose of the study was to test the emission from the facilities, and determine if they match the requirements. The results of the study was that compared to estimates of annual forest fire emissions in Canada, the oil sands facilities are a minor source of aerosol number, aerosol mass, particulate organic matter, and black carbon.
=== Magnetic === Magnetic refrigerators are refrigerators that work on the magnetocaloric effect. The cooling effect is triggered by placing a metal alloy in a magnetic field. Acoustic refrigerators are refrigerators that use resonant linear reciprocating motors/alternators to generate a sound that is converted to heat and cold using compressed helium gas. The heat is discarded and the cold is routed to the refrigerator.
Sources: en.wikipedia.org
91E Allied Trades Specialist (formerly 91E and 91W) 91F Small Arms/Towed Artillery Repairer (formerly 45B) 91G Fire Control Repairer (formerly 45G) 91H Track Vehicle Repairer (formerly 63H) 91J Quartermaster and Chemical Equipment Repairer (formerly 63J) 91L Construction Equipment Repairer (formerly 62B) 91M Bradley Fighting Vehicle System Maintainer (formerly 63T) 91P Self Propelled Artillery Systems Maintainer (formerly 63D) 91S Stryker Systems Maintainer 91X Maintenance Supervisor (formerly 63X) 91Z Senior Maintenance Supervisor (formerly 63Z) 94A Land Combat Electronic Missile System Repairer (formerly 27E) 94D Air Traffic Control Equipment Repairer 94E Radio & Communications Security (COMSEC) Equipment Repairer 94F Computer/Detection Systems Repairer 94H Test Measurement and Diagnostic Equipment (TMDE) Maintenance Support Specialist 94M Radar Repairer 94P Multiple Launch Rocket System (MLRS) Repairer (formerly 27M) 94R Avionic and Survivability Repairer 94S PATRIOT System Repairer 94T AVENGER System Repairer 94W Electronic Maintenance Chief (ARNG) 94X Senior Missile Systems Maintainer 94Y Integrated Family of Test Equipment (IFTE) Operator/Maintainer 94Z Senior Electronic Maintenance Chief
Pumping protons out of the mitochondria creates a proton concentration difference across the membrane and generates an electrochemical gradient. This force drives protons back into the mitochondrion through the base of an enzyme called ATP synthase. The flow of protons makes the stalk subunit rotate, causing the active site of the synthase domain to change shape and phosphorylate adenosine diphosphate—turning it into ATP.
In cardiology, the cardiac skeleton, also known as the fibrous skeleton of the heart, is a high-density homogeneous structure of connective tissue that forms and anchors the valves of the heart, and influences the forces exerted by and through them. The cardiac skeleton separates and partitions the atria (the smaller, upper two chambers) from the ventricles (the larger, lower two chambers). The heart's cardiac skeleton comprises four dense connective tissue rings that encircle the mitral and tricuspid atrioventricular (AV) canals and extend to the origins of the pulmonary trunk and aorta. This provides crucial support and structure to the heart while also serving to electrically isolate the atria from the ventricles. The unique matrix of connective tissue within the cardiac skeleton isolates electrical influence within these defined chambers. In normal anatomy, there is only one conduit for electrical conduction from the upper chambers to the lower chambers, known as the atrioventricular node. The physiologic cardiac skeleton forms a firewall governing autonomic/electrical influence until bordering the bundle of His which further governs autonomic flow to the bundle branches of the ventricles. Understood as such, the cardiac skeleton efficiently centers and robustly funnels electrical energy from the atria to the ventricles.
Ibogaine biosynthesis begins with tryptophan undergoing enzymatic decarboxylation by tryptophan decarboxylase (TDC) to form tryptamine. Secologanin, an iridoid synthesized from isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP), is reacted with tryptamine to make strictosidine. A glycosidic bond cleavage of strictosidine by strictosidine β-deglucosidase (SGD) produces a lactol. The lactol opens and produces an aldehyde, then condenses to form an iminium. Through isomerization and reduction by geissoschizine synthase 1 (GS1), 19E-geissoschizine is yielded. The indole is oxidized, and the molecule undergoes an intramolecular Mannich reaction and Grob fragmentation to form preakuammicine. Preakuammicine is highly unstable and therefore reduced to stemmadenine by oxidation-reduction reactions (REDOX 1 and REDOX 2). Stemmadine is acylated by stemmadine Ο-acetyltransferase (SAT) to yield stemmadine acetate. Through oxidation by precondylocarpine acetate synthase (PAS) and reduction by dihydroprecondylocarpine acetate synthase (DPAS), an enamine intermediate is formed. The intermediate undergoes fragmentation to produce an iminium that tautomerizes to yield dehydrosecodine. Coronaridine synthase (CorS) catalyzes the isomerization of dehydrosecodine, and an unusual cycloaddition is completed. DPAS and NADPH reduce the iminium to form (-)-coronaridine. There are two pathways (-)-coronaridine can take to become (-)-ibogaine.
== Adverse effects == People have experienced serious infections due to abatacept's suppression of the immune system; some of these infections have been fatal. People with COPD are likely to get lung infections more often than usual. Some people have had anaphylactic reactions to the drug. Abatacept may cause otherwise slow-growing cancers to proliferate and spread, due to suppression of the immune system. Very common adverse effects (occurring in more than 10% of people) include upper respiratory tract infections. Common adverse effects (occurring in between 1% and 10% of people) include lower respiratory tract infections, urinary tract infections, herpes infections, pneumonia, flu, cough, high blood pressure, stomach pain, diarrhea, nausea, vomiting, upset stomach, mouth sores, elevated transaminases, rashes, fatigue, weakness, local injection site reactions, and systemic injection reactions.
Sources: en.wikipedia.org
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.
Growth hormone released from the pituitary stimulates IGF-1 production in the liver and other tissues, so circulating IGF-1 generally rises during exposure. The size of the rise varies between individuals and depends on baseline hormonal status and other concurrent factors.
Reported imaging studies focus on visceral adipose tissue, where reductions are more consistently observed across trials. Subcutaneous depots show smaller and less reproducible changes, so the two compartments should not be treated as equivalent.
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.